This study provides preliminary evidence in support of GLP-1 based therapies in providing beneficial effects against atherosclerosis as this therapeutic regimen was found to be associated with statistically significant reductions in the plasma levels of atherosclerosis markers including plasminogen activator inhibitor-1, high sensitivity c-reactive protein, and brain natriuretic peptide. This evidence concerns the gene SERPINE1 and atherosclerosis.